Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway? | Zendy

Mahmut İlker Yılmaz | Zendy; Alper Sönmez | Zendy; Mutlu Sağlam | Zendy; Hüseyin Yaman | Zendy; Tuncer Çaycı | Zendy; Selim Kılıç | Zendy; Tayfun Eyıleten | Zendy; K. Çağlar | Zendy; Y. Oğuz | Zendy; Abdülgaffar Vural | Zendy; Müjdat Yenicesu | Zendy; John Axelsson | Zendy

Open Access

Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?

Author(s) -

Mahmut İlker Yılmaz,

Alper Sönmez,

Mutlu Sağlam,

Hüseyin Yaman,

Tuncer Çaycı,

Selim Kılıç,

Tayfun Eyıleten,

K. Çağlar,

Y. Oğuz,

Abdülgaffar Vural,

Müjdat Yenicesu,

John Axelsson

Publication year - 2010

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfq159

Subject(s) - medicine , ramipril , endocrinology , proteinuria , asymmetric dimethylarginine , diabetic nephropathy , renal function , kidney disease , endothelial dysfunction , diabetes mellitus , nephropathy , blood pressure , kidney , arginine , biochemistry , chemistry , amino acid

Renin-angiotensin system (RAS) blockade improves proteinuria and the endothelial functions in diabetic nephropathy. Plasma asymmetric dimethylarginine (ADMA), abundant in the cell than in the plasma, is also improved by RAS blockage. We hypothesized that RAS blockade may reduce ADMA by reducing injurious cell death.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research